Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Nalmefene, alcohol dependence
Naloxone injection or intranasal treatment opioid overdose treatment
Naltrexone borderline personality disorder for antipsychotic-induced weight gain for tardive dyskinesia gambling disorder people with learning difficulties preventing relapse after alcohol detoxification preventing relapse after opioid detoxification
Naranjo adverse drug reaction scale (adapted) 972
Naranjo scale anticholinergic effects of antipsychotics antipsychotics in menopausal women Summary of psychiatric adverse effects of non-psychotropics
National Confidential Inquiry into Suicide and Homicide by People with Mental Illness
National Institute for Health and Care Excellence (NICE) guidelines anxiety spectrum disorders attention deficit hyperactivity disorder in adults attention deficit hyperactivity disorder in children and adolescents borderline personality disorder dementia depression eating disorders generalised anxiety disorder hypercholesterolaemia obsessive compulsive disorder panic disorder prophylaxis in bipolar disorder
Natural
Neurobiology of withdrawal
Neuroleptic malignant syndrome
Neuroleptic malignant syndrome association Neuroleptic malignant syndrome optimal dosage relative efficacy treatment algorithm treatment of negative symptoms
new psychoactive substances (NPS/designer drugs) 477 Benzodiazepine misuse Drug-induced excited state
Next-steps if no response
NICE guidelines
Nicotine attention deficit hyperactivity disorder depression and anxiety drug interactions movement disorders Nicotine psychotropic effects schizophrenia smoking cessation and withdrawal symptoms
Nicotine dependence bupropion cytisine electronic vaping devices Nicotine Nicotine and smoking cessation nicotine replacement therapy treatment algorithms varenicline withdrawal symptoms
Nicotine preparations and doses
nicotine replacement therapy (NRT) 523-524 adverse effects clinical effectiveness combination of formulations preparations and doses
Nicotine vaping devices (vaping) 527-528 adverse effects clinical effectiveness Nicotine and smoking cessation preparations and doses
Nocebo effects, patient expectations of treatment
Nocturnal enuresis, management
Non-adherence impacts lithium rates and degrees of adherence restarting psychotropic medications after period of non-compliance
non-competitive N-methyl-D-aspartate receptor antagonists
Non-iatrogenic benzodiazepine dependence
Non-nucleoside reverse transcriptase inhibitors
Non-psychotropics associated with QT prolongation (see Crediblemeds.org for latest information; this is not a complete list).
non-steroidal anti-inflammatory drugs (NSAIDs)
Norclozapine
Nucleoside reverse transcriptase inhibitors, psychiatric adverse reactions
Nutritional supplements anorexia nervosa fatigue in multiple sclerosis